-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The novel coronavirus has infected hundreds of millions of people around the world since its outbreak in 2019, causing more than 3.
In the early stage of the new crown pandemic, due to the low infection rate and incidence of SARS-CoV-2, the child SARS-CoV-2 infection vaccine project is not a priority, and whether younger children should be vaccinated and related safety The problem, people still have a lot of questions
Up to now, there have been a variety of children's new crown vaccines that have begun to show signs
Therefore, in order to further verify the preventive benefits of the vaccine against younger children, prevent infants from becoming SARS-CoV-2 virus reservoirs, and protect infants from the virus, including infants in the SARS-CoV-2 global pediatric vaccine plan is important for prevention.
To achieve this goal, Dr.
In order to evaluate the preventive effect of the SARS-CoV-2 infant vaccine, the researchers immunized 2.
Evaluation of the immunogenicity of two SARS-CoV-2 vaccines in infant rhesus monkeys
Subsequently, the researchers evaluated the immune response induced by the infant vaccine within 22 weeks.
Binding antibody response triggered by SARS-CoV-2 vaccine in rhesus monkeys
Not only that, the study found that the neutralizing antibody kinetics induced by the two vaccines were consistent with the plasma binding antibody kinetics and persisted during the study
As we all know, neutralizing antibodies play an important role in virus clearance and can be used to protect or treat viral diseases
However, the level and effect of SARS-CoV-2 specific neutralizing antibodies are not yet clear
This latest study found that in the 22nd and 18th weeks after receiving the second immunization, the antibody titer of the pseudovirus (PsV) of the Protein-3M-052-SE vaccine group still exceeded 103, and the mRNA-LNP vaccine The group exceeds 102
Functional antibody response induced by SARS-CoV-2 vaccine in infants of rhesus monkeys
Note: The original text has been deleted
Reference materials:
[1]https://immunology.
